Now, researchers from Stanford Medicine have identified a naturally occurring molecule that mimics semaglutide's effects but appears to avoid these drawbacks in a study recently published in Nature.

That's because the drug's manufacturer, the Danish pharmaceutical company Novo Nordisk, has a patent on the semaglutide molecule, making it the sole source for compounding pharmacies. And the ...

Stanford Medicine scientists have discovered a naturally occurring molecule that rivals the weight-loss effects of semaglutide-based GLP-1s in animals — without the dreaded side effects.

Valcarce said the small molecule nature of TTP273 makes it ideal for an oral formulation. Novo Nordisk’s next generation GLP-1 semaglutide is a larger peptide-based drug, which is more difficult ...

CagriSema (a combination of cagrilintide and Semaglutide); the small molecule oral cannabinoid receptor 1 (CB1) inverse agonist, Monlunabant; and triple agonist retatrutide. 18 Dr. Liji Thomas is ...